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Abstract
Objectives—To develop 3 computer simulation models to determine the potential economic
effect of using intravenous (IV) antiviral agents to treat hospitalized patients with influenza-like
illness, as well as different testing and treatment strategies.
Study Design—Stochastic decision analytic computer simulation model.
Methods—During the 2009 influenza A(H1N1) pandemic, the Food and Drug Administration
granted emergency use authorization of IV neuraminidase inhibitors for hospitalized patients with
influenza, creating a need for rapid decision analyses to help guide use. We compared the
economic value from the societal and third-party payer perspectives of the following 4 strategies
for a patient hospitalized with influenza-like illness and unable to take oral antiviral agents:
Strategy 1: Administration of IV antiviral agents without polymerase chain reaction influenza
testing. Strategy 2: Initiation of IV antiviral treatment, followed by polymerase chain reaction
testing to determine whether the treatment should be continued. Strategy 3: Performance of
polymerase chain reaction testing, followed by initiation of IV antiviral treatment if the test results
are positive. Strategy 4: Administration of no IV antiviral agents. Sensitivity analyses varied the
probability of having influenza (baseline, 10%; range, 10%–30%), IV antiviral efficacy (baseline,
oral oseltamivir phosphate; range, 25%–75%), IV antiviral daily cost (range, $20–$1000), IV
antiviral reduction of illness duration (baseline, 1 day; range, 1–2 days), and ventilated vs
nonventilated status of the patient.
Results—When the cost of IV antiviral agents was no more than $500 per day, the incremental
cost-effectiveness ratio for most of the IV antiviral treatment strategies was less than $10,000 per
quality-adjusted life-year compared with no treatment. When the cost was no more than $100 per
day, all 3 IV antiviral strategies were even more cost-effective. The order of cost-effectiveness
from most to least was strategies 3, 1, and 2. The findings were robust to changing risk of
influenza, influenza mortality, IV antiviral efficacy, IV antiviral daily cost, IV antiviral reduction
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of illness duration, and ventilated vs nonventilated status of the patient for both societal and third-
party payer perspectives.
Conclusion—Our study supports the use of IV antiviral treatment for hospitalized patients with
influenza-like illness.
The 2009 influenza A(H1N1) pandemic raised questions about the role of intravenous (IV)
antiviral medications in treating hospitalized (ventilated and nonventilated) patients with
influenza-like illness (ILI). Intravenous neuraminidase inhibitors had been under rapid
development, with IV peramivir receiving emergency use authorization (EUA) from the
Food and Drug Administration (FDA) in October 2009, after the US Secretary of Health and
Human Services declared a public health emergency.1–3 The primary motivation for EUA
was a lack of alternative drugs for hospitalized patients with influenza A(H1N1) who were
unable to take oral or inhaled antiviral agents. Standard FDA approval was not a viable
option because efficacy and safety data were limited and the pandemic was already in full
bloom. The EUA allowed healthcare providers to administer IV peramivir to patients
hospitalized with confirmed or suspected influenza A(H1N1) only if they were unresponsive
to or unable to take oral or inhaled antiviral agents.1,3 Contraindications included a history
of severe allergic reaction to neuraminidase inhibitors.3
Antiviral medications are the only medications available to reduce the morbidity and
mortality of individuals infected with influenza. Neuraminidase inhibitors are an important
and widely used class of antiviral agents, the most commonly used being oral oseltamivir
phosphate and inhaled zanamivir (both approved by the FDA in 1999).4 In influenza A and
influenza B, an enzyme cleaves links between the infected host cell and the influenza virus
envelope. This, in turn, allows the viruses that replicated in the host cell to be released to the
rest of the body.5 By inhibiting viral replication and thereby limiting the number of viruses
in the body, neuraminidase inhibitors could reduce the duration of illness and risk of
mortality.6
Because IV peramivir was a novel drug, there were no available clinical trials among higher-
risk groups such as pregnant women, pediatric patients, and older adults. It was also unclear
how viral resistance to other neuraminidase inhibitors may translate to resistance to
peramivir.6
Intravenous antiviral agents such as peramivir have several potential advantages. First, they
offer an alternative route of administration, which is especially important for patients who
cannot take medication by mouth (such as ventilated patients). Second, when heavy demand
may deplete inventories of other antiviral agents such as oseltamivir and zanamivir, IV
antiviral agents can serve as another available option. Third, there remains the possibility
that strains resistant to other antiviral agents may not be completely resistant to newer
antiviral agents such as peramivir, although evidence suggests that oseltamivir-resistant
strains may also be resistant to peramivir.7
Intravenous antiviral agents have only recently emerged as potential treatment options, and
questions remain about their economic value. Should they be reserved for intensive care unit
patients or administered to all hospitalized patients with influenza who cannot take oral
antiviral agents? What is a reasonable price for IV antiviral medications? How would the
value of IV antiviral agents change with emerging resistance? Should patients be tested for
influenza before the initiation of IV antiviral agents, or should IV antiviral treatment be
initiated first, followed by confirmatory testing to determine whether treatment should be
continued? Will the value be different for seasonal vs pandemic influenza?
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We developed 3 computer simulation models to estimate the potential economic effect of
using IV antiviral agents to treat hospitalized patients with ILI, as well as different testing
and treatment strategies. Various simulation runs explored seasonal and pandemic influenza
scenarios and evaluated the effects of varying patient age, probability of having influenza,
ventilated vs nonventilated status of the patient, and the probability of different influenza
outcomes such as mortality.
METHODS
Structure of the Model
The Figure shows the general structure of our Monte Carlo decision analytic computer
simulation model, constructed using commercially available software (TreeAge Pro 2009;
TreeAge Software, Williamstown, Massachusetts). Our model represented the economic
value from the societal and third-party payer perspectives of the following 4 alternative
strategies for a patient hospitalized with ILI and unable to take oral antiviral agents, as per
the EUA1–3:
Strategy 1: Administration of IV Antiviral Agents Without Polymerase Chain
Reaction (PCR) Influenza Testing—In this strategy, the patient received a full 5-day
course of IV antiviral agents regardless of whether the patient actually had influenza. No
PCR influenza testing was performed.
Strategy 2: Initiation of IV Antiviral Treatment, Followed by PCR Testing to
Determine Whether the Treatment Should Be Continued—This strategy involved
initiation of IV antiviral treatment for hospitalized patients with ILI and then performance of
PCR testing for influenza, which required a 24-hour turnaround time for results. A negative
test result prompted discontinuation of IV antiviral treatment after a single dose.
Strategy 3: Performance of PCR Testing, Followed by Initiation of IV Antiviral
Treatment If the Test Results Were Positive—For this strategy, IV antiviral agents
would not be initiated until PCR testing was performed and results were available, delaying
treatment for 24 hours. A positive test result prompted initiation of IV antiviral treatment.
Strategy 4: Administration of No IV Antiviral Agents—This strategy involved
giving no medical interventions as the treatment.
Each simulated adult traveled through the decision tree pictured in the Figure and faced a
probability draw (first-order trial) at each chance node. This draw was then compared with a
value pulled from the probability parameter distribution to determine down which branch he
or she traveled (second-order trials). The costs, utilities, and durations of each resulting
outcome also drew from their respective probability distributions (second-order trials). Each
patient had a probability of having influenza (baseline, 10%).8,9 Test results depended on
whether the patient actually had influenza, and the sensitivity and specificity of the test.
Intravenous antiviral treatment had a probability (IV antiviral efficacy) of reducing the
duration of illness by 1 day (ie, if the dice roll is less than the efficacy number, then the
illness duration is reduced; if it is higher, then there is no effect) and the risk of mortality (ie,
mortality is reduced by 1 minus IV antiviral efficacy).
Scenarios from the third-party payer perspective considered only the direct costs of illness,
while scenarios from the societal perspective included both direct and indirect costs of
illness (ie, productivity losses from caregiver time determined by lost wages from time spent
with the patient). Each simulation run sent 1000 simulated adults 1000 times through each
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model, for a total of 1,000,000 trials per scenario. During each run, each parameter drew
from the relevant triangular or beta distributions. Table 1 lists the study sources of data
inputs for the model.8,10–24
The following equation calculated the incremental cost-effectiveness ratio (ICER) of each
strategy vs the comparator strategy: Coststrategy x − Coststrategy y = Effectivenessstrategy x −
Effectivenessstrategy y, where x represents the strategy and y represents the comparator
strategy.
Each simulation run generated a mean ICER and a 95% confidence interval. A strategy was
considered cost-effective if the ICER was less than $50,000 per quality-adjusted life-year
(QALY).16 However, because there is some debate about the exact threshold for cost-
effectiveness, we report the resulting ICER values so that individual readers may make their
own determination of what constitutes a cost-effective intervention.
Data Inputs
The study used various inputs and their corresponding distributions for the probabilities,
costs, durations, and utilities in the model. Hospital mortality from influenza drew from a
beta distribution. All other variables drew from triangular distributions. A 3% discount rate
converted all past and future costs to 2009 values.25
Because PCR testing is unavailable and is not part of standard care in many inpatient
settings, our model did not include PCR test costs for the IV antiviral and no IV antiviral
strategies.26 The hospitalization costs for these arms did not include PCR testing. The PCR
test costs were added to the 2 strategies that included PCR testing.
Effectiveness was measured in QALYs. Influenza caused QALY decrements for the
duration of illness.17,18 All QALY accruals were age adjusted based on the quality-of-life
utility obtained by Gold et al.16 Patients who survived accrued age-adjusted and discounted
(3% discount rate) QALYs based on life-expectancy estimates from the Human Mortality
Database; patients who did not survive did not accrue these QALYs.16,27
Sensitivity Analysis
Probabilistic (Monte Carlo) sensitivity analyses explored all parameters simultaneously
using all distributions examined. Sensitivity analysis varied these following key variables:
the probability of having influenza (baseline, 10%; range, 10%–30%),9 IV antiviral efficacy
(baseline, oral oseltamivir; range, 25%–75%), IV antiviral daily cost (baseline, $20 [oral
oseltamivir]; range, $20–$1000), IV antiviral reduction of illness duration (baseline, 1 day;
range, 1–2 days), patient age (baseline, 20 years; range, 20–60 years), and influenza
mortality (baseline, seasonal influenza mortality; range, up to twice the seasonal influenza
mortality for a pandemic scenario). These sensitivity analyses involved fixing the variable of
interest and then allowing the rest to pull from the distributions examined. We evaluated
seasonal and pandemic influenza scenarios, as well as IV antiviral treatment in ventilated
and nonventilated patients.
RESULTS
Table 2 and Table 3 give the results at baseline, while varying IV antiviral efficacy (25%–
75%) (ie, the proportion by which IV antiviral agents will reduce mortality) and IV antiviral
daily cost from the third-party payer perspective for the seasonal and pandemic scenarios.
Each table gives the ICER (compared with the most economically favorable option) for each
strategy. Calculated ICER 95% confidence intervals demonstrated no overlaps, suggesting
that the differences were significant.
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For the ventilated population under seasonal influenza conditions, the ICER of the IV
antiviral treatment vs no treatment was less than $10,000 per QALY in most scenarios, as
long as the IV antiviral cost was no more than $500 per day, except for strategy 2 (initiation
of IV antiviral treatment, followed by PCR testing to determine whether the treatment
should be continued). In fact, when IV antiviral cost was no more than $100 per day, all 3
IV antiviral strategies were even more cost-effective (ie, provided cost and health benefits)
than no treatment, with the order from most to least cost-effective being strategies 3
(performance of PCR testing, followed by initiation of IV antiviral treatment if the test
results are positive), 1 (administration of IV antiviral agents without PCR influenza testing),
and 2 (initiation of IV antiviral treatment, followed by PCR testing to determine whether the
treatment should be continued). As the risk of influenza increased from 10%, the antiviral
strategies grew even more economically favorable. Similarly, increasing the IV antiviral
illness reduction effect to 2 days further enhanced the cost-effectiveness of all IV antiviral
strategies.
These findings were robust to various sensitivity analyses. Pandemic conditions increased
the economic value of only the IV antiviral strategies. The order of cost-effectiveness of the
strategies did not change as long as IV antiviral treatment cost no more than $100 per day.
Switching from the third-party payer perspective to the societal perspective captured
additional cost savings for the IV antiviral strategies.
Nonventilated Population
Findings for the nonventilated population were similar to those for the ventilated population.
Although the IV antiviral strategies were slightly less cost-effective for the comparatively
healthier nonventilated population, the ICERs for most of the IV antiviral strategies fell far
below $10,000 per QALY when the IV antiviral cost was no more than $100 per day. The
results of sensitivity analyses for the nonventilated population were not substantially
different from those for the ventilated population.
DISCUSSION
With the 2009 pandemic and concerns that the circulating influenza A(H1N1) virus might be
more virulent than typical circulating seasonal influenza viruses, the US Secretary of Health
and Human Services indicated that certain influenza A(H1N1) interventions might be
approved for emergency use. On October 23, 2009, the FDA granted EUA for IV peramivir
with the following restrictions1–3: (1) it was to be used only to treat patients hospitalized
with the 2009 influenza A(H1N1) virus and (2) patients treated had to have laboratory-
confirmed 2009 influenza A(H1N1) virus infection or an unidentifiable subtype of influenza
A virus suspected to be influenza A(H1N1) virus and be (a) someone who was unresponsive
to oral or inhaled antiviral therapy or (b) someone in whom drug delivery through enteral
(eg, oseltamivir) or inhaled (eg, zanamivir) routes was not feasible.
Our study strongly supports the use of IV antiviral agents for hospitalized patients with
severe influenza complications during influenza A(H1N1) pandemic and other influenza
seasons. The results also suggest that initial use of PCR testing to guide IV antiviral
treatment continuation may be more cost-effective. Our finding that this strategy is
economically dominant is especially compelling because interventions that not only save
lives, but also decrease costs are uncommon. Our study supports IV antiviral treatment in
ventilated and nonventilated patients.
Determining the epidemiological and clinical characteristics of the influenza A(H1N1)
pandemic was challenging. As the pandemic progressed, attack rate and mortality estimates
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changed on a weekly basis. Therefore, our goal was to use conservative initial values for our
model to establish thresholds above which IV antiviral treatment would no longer be cost-
effective. Because we determined that the IV antiviral agents and PCR strategy would be
cost-effective and in most cases economically dominant, even at seasonal influenza
parameters as long as the influenza A(H1N1) strain was at least as virulent as typical
seasonal influenza strains, such a strategy is justified during a pandemic.
Peramivir has several advantages over other neuraminidase inhibitors. It was the only
available IV neuraminidase inhibitor during the 2009 influenza A(H1N1) pandemic. With a
reported efficacy similar to that of oral antiviral agents, peramivir provides an alternative
drug route for patients who have an inability to take oral medications, poor gastrointestinal
absorption, or any other respiratory illness that requires mechanical ventilation. Intravenous
administration can also help ensure patient compliance with receiving the full course of
antiviral agents (many patients may not complete the full course of oral or inhaled antiviral
agents). Conversely, because IV peramivir has not undergone nearly as much testing as
oseltamivir and zanamivir, efficacy and safety data are limited, rendering extensive cross-
comparisons between peramivir and other antiviral agents difficult. Resistance to other
antiviral medications may lead to resistance to peramivir and vice versa. For example, the
FDA reported that some influenza viruses that are highly resistant to oseltamivir were also
cross-resistant to peramivir via the H275 resistance gene.7 In another study,28 the resistance
profile of zanamivir was better than that of peramivir.
Price is also an important issue when a new therapy reaches the market. Although these
decisions involve several factors, our study helps benchmark what levels of pricing may be
appropriate. The benefits of IV antiviral agents support a higher price point than that of oral
antiviral agents. However, it is unclear how different pricing levels may affect adoption of
use.
Our model aimed to underestimate the value of IV antiviral treatment. We did not quantify
the potential benefit of decreased viral shedding with the use of IV antiviral agents. In
addition, our pandemic scenarios represent an influenza pandemic with twice the mortality
rate of seasonal influenza. Higher mortality rates would only strengthen the results of our
study.
There are several limitations to our study. No computer model can fully represent every
possible influenza event and outcome. By definition, models are simplifications of real life.
Our study assumed that patients were admitted to the hospital primarily for ILI and did not
have other major comorbidities that would contribute to mortality. However, the effect of
comorbidities in real life can be variable and unexpected. Moreover, this may increase
corresponding resource-use (eg, intubation and mechanical ventilation). Our model did not
incorporate the possible adverse effects of IV antiviral medications. Moreover, our study did
not consider the potential effects of IV antiviral medications on transmission and
communicability (ie, IV antiviral medications may decrease the degree and duration of
influenza virus shedding).
CONCLUSIONS
During the 2009 influenza A(H1N1) pandemic, the FDA granted EUA of IV neuraminidase
inhibitors for hospitalized patients with influenza, creating a need for rapid economic studies
to help guide their use. Our study supports the use of IV antiviral treatment for hospitalized
patients (ventilated and nonventilated) with ILI. If available, initial PCR testing to help
guide treatment may be an even more cost-effective strategy. The use of IV antiviral agents
in this setting may save money and offer health benefits.
Lee et al. Page 6














Funding Source: This study was funded by grant 5U54GM088491-02 from the National Institute of General
Medical Sciences Models of Infectious Disease Agent Study, 5R01LM009132-03 from the National Library of
Medicine, and 5P01HK000086-02 from the Centers for Disease Control and Prevention. The funders had no role in
the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
1. U.S. Food and Drug Administration. [Accessed December 17, 2010] FDA authorizes emergency use
of intravenous antiviral peramivir for 2009 H1N1 influenza for certain patients, settings. Oct 23.
2009 http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm187813.htm
2. Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1
influenza. N Engl J Med. 2009; 361(23):2204–2207. [PubMed: 19884645]
3. Centers for Disease Control and Prevention. H1N1 Flu: Emergency Use Authorization (EUA) of
Medical Products and Devices: Peramivir IV. Atlanta, GA: Dept of Health and Human Services;
2009.
4. U.S. Food and Drug Administration. [Accessed December 17, 2010] Drugs@FDA: FDA approved
drug products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
5. Centers for Disease Control and Prevention. Neuraminidase inhibitors for treatment of influenza A
and B infections [published correction appears in MMWR Morb Mortal Wkly Rep. 1999;48(49):
1139]. MMWR Recomm Rep. 1999; 48(RR-14):1–9.
6. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005; 353(13):1363–1373.
[PubMed: 16192481]
7. U.S. Food and Drug Administration. [Accessed December 17, 2010] Peramivir IV questions and
answers for health care providers. http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/ucm187980.htm
8. Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project. HCUP facts
and figures: statistics on hospital-based care in the United States. [Accessed December 17, 2010]
9. Centers for Disease Control and Prevention. [Accessed December 17, 2010] Flu activity &
surveillance: past weekly surveillance reports. http://www.cdc.gov/flu/weekly/fluactivity.htm
10. PDR Red Book: Pharmacy’s Fundamental Reference. Montvale, NJ: Thompson Healthcare Inc;
2009.
11. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared
with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness
analysis. Ann Intern Med. 1999; 130(10):789–799. [PubMed: 10366368]
12. Bureau of Labor Statistics. [Accessed December 17, 2010] Occupational employment statistics:
May 2008 national occupational employment and wage estimates: United States. http://
www.bls.gov/oes/2008/may/oes_nat.htm
13. Syrmis MW, Whiley DM, Thomas M, et al. A sensitive, specific, and cost-effective multiplex
reverse transcriptase–PCR assay for the detection of seven common respiratory viruses in
respiratory samples. J Mol Diagn. 2004; 6(2):125–131. [PubMed: 15096568]
14. Chidlow G, Harnett G, Williams S, Levy A, Speers D, Smith DW. Duplex real-time reverse
transcriptase PCR assays for rapid detection and identification of pandemic (H1N1) 2009 and
seasonal influenza A/H1, A/H3, and B viruses. J Clin Microbiol. 2010; 48(3):862–866. [PubMed:
20071557]
15. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1)
infection in Canada. JAMA. 2009; 302(17):1872–1879. [PubMed: 19822627]
16. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using
national measures to create condition-specific values. Med Care. 1998; 36(6):778–792. [PubMed:
9630120]
17. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public.
J Chronic Dis. 1978; 31(11):697–704. [PubMed: 730825]
Lee et al. Page 7













18. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;
38(6):583–637. [PubMed: 10843310]
19. Jain S, Kamimoto L, Bramley AM, et al. 2009 Pandemic Influenza A (H1N1) Virus
Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the
United States, April–June 2009. N Engl J Med. 2009; 361(20):1935–1944. [PubMed: 19815859]
20. Rello J, Rodríguez A, Ibañez P, et al. H1N1 SEMICYUC Working Group. Intensive care adult
patients with severe respiratory failure caused by influenza A (H1N1)v in Spain. Crit Care. 2009;
13(5):eR148.
21. Li G, Yilmaz M, Kojicic M, et al. Outcome of critically ill patients with influenza virus infection. J
Clin Virol. 2009; 46(3):275–278. [PubMed: 19699141]
22. Bureau of Labor Statistics. [Accessed December 17, 2010] Employment characteristics of families
in 2008. May 27. 2009 http://www.bls.gov/news.release/archives/fa-mee_05272009.pdf
23. Bureau of Labor Statistics. [Accessed December 17, 2010] Employment characteristics of families
in 2007. http://www.bls.gov/news.release/archives/famee_05302008.pdf
24. Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. Neuraminidase inhibitors for
preventing and treating influenza in healthy adults. Cochrane Database Syst Rev. 2006;
3:CD001265. [PubMed: 16855962]
25. Shepard, DS. Cost-effectiveness in Health and Medicine. Gold, MR.; Siegel, JE.; Russell, LB.;
Weinstein, MC., editors. New York: Oxford University Press; 1996. J Ment Health Policy Econ.
1999; 2(2):91–92. [PubMed: 11967415]
26. Centers for Disease Control and Prevention. [Accessed December 17, 2010] Influenza diagnostic
testing during the 2009–2010 flu season. Sep 29. 2009 http://www.cdc.gov/h1n1flu/
diagnostic_testing_public_qa.htm
27. Wilmoth, JR.; Shkolnikov, V. [Accessed December 17, 2010] Human Mortality Database. 2008.
http://www.mortality.org/
28. Dulek DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of
oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic
influenza A (H1N1) virus. Clin Infect Dis. 2010; 50(11):1493–1496. [PubMed: 20415572]
Lee et al. Page 8














During the 2009 influenza A(H1N1) pandemic, the Food and Drug Administration
granted emergency use authorization of peramivir because of a dearth of alternative drugs
for patients unable to take oral or inhaled antiviral agents and because of limited safety
and efficacy data for peramivir. Our economic model suggests the following:
• Intravenous antiviral agents are a cost-effective intervention for hospitalized
patients with severe influenza-like illness.
• The use of PCR influenza testing to guide whether to initiate intravenous
antiviral treatment is the most cost-effective strategy.
• The use of intravenous antiviral agents in this setting may save money and offer
health benefits.
• Our findings should help guide policy makers and clinicians in the use of such
novel treatments during other influenza seasons.
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Figure. Decision Tree Model
IV indicates intravenous; PCR, polymerase chain reaction; TP, true positive; FN, false
negative; FP, false positive; TN, true negative.
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Table 1
Data Inputs for Model Variables
Description Mean
95% Range
SourceLower Limit Upper Limit
Costs, US $
IV antiviral peramivira 20 — — PDR Red Book10
Hospitalization per day
 18–44 y 1822 1037 2607 AHRQ8
 45–64 y 1465 110 2820 AHRQ8
 65–84 y 1333 805 1861 AHRQ8
Ventilation per day
 18–44 y 2397 1605 3189 AHRQ8
 45–64 y 2194 1611 2777 AHRQ8
 65–84 y 2066 1545 2587 AHRQ8
Death in hospital 6921 5191 9025 AHRQ8; Gould et al11
Median hourly wageb 15.57 8.59 42.15 Bureau of Labor Statistics12
PCR test 10 7.37 29 Syrmis et al13; Chidlow et al14
Durations
Hospitalized, dc
 18–44 y 2 1.8 2.2 AHRQ8
 45–64 y 3 2.7 3.3 AHRQ8
 65–84 y 4 3.8 4.2 AHRQ8
Ventilated, dd 12 6 20 Kumar et al15
Hourly wage, US $ 8 — Assumption
Utilities
1 y Of adult life, QALY
 20–64 y 0.92 — — Gold et al16
 65–70 y 0.84 — — Gold et al16
Utility
 Influenza with hospitalization, QALY 0.5 0.38 0.63 Sackett and Torrance17; Tengs and Wallace18
Probabilities
Clinical outcomes without vaccination
 Mortality given influenza with hospitalization
  18–44 y 0.0099 0.0086 0.0112 AHRQ8
  45–64 y 0.0099 0.0086 0.0112 AHRQ8
  65–84 y 0.0144 0.0117 0.0171 AHRQ8
 Mortality given influenza with ventilation 0.45 0.33 0.52 Jain et al19; Rello et al20; Li et al21
Parents’ income with children <18 y old Bureau of Labor Statistics22,23
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Description Mean
95% Range
SourceLower Limit Upper Limit
 Single income 0.1370 0.0374 0.2366
 Dual income 0.4816 0.4803 0.4832
PCR test
 Sensitivity 0.963 0.815 0.988 Chidlow et al14
 Specificity 0.996 0.989 1 Chidlow et al14
IV antiviral efficacye 0.78 0 0.98 Jefferson et al24
AHRQ indicates Agency for Healthcare Research and Quality; IV, intravenous; PCR, polymerase chain reaction; QALY, quality-adjusted life-year.
a
Sensitivity analyses on daily cost of IV antiviral agents (baseline oseltamivir phosphate, $20, $100, $500, and $1000).
b






Baseline IV antiviral based on oral oseltamivir, symptom reduction, and hospital stay for 1 d.
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Table 2
ICERs of Different Intravenous Antiviral Strategies in the Ventilated Population From the Third-Party Payer
Perspectivea
Variable
IV Antiviral Efficacy in Reducing Hospital Stay by 1 d, ICER
25% 50% 75%
Seasonal Influenza Scenario
IV antiviral cost of $100 per day
 PCR testing, then start IV antiviral agents — — —
 Start IV antiviral agents, then PCR
testing
39,674 39,674 39,674
 Give no IV antiviral agent Dominated by start IV
antiviral agents, then PCR
testing
Dominated by start IV
antiviral agents, then PCR
testing
Dominated by start IV antiviral
agents, then PCR testing
 Give IV antiviral agents 69 67 67
IV antiviral cost of $500 per day
 PCR testing, then start IV antiviral agents 41 — —
 Give no IV antiviral agent — Dominated by PCR testing,
then start IV antiviral agents
Dominated by PCR testing,
then start IV antiviral agents
 Start IV antiviral agents, then PCR
testing
198,370 198,370 198,370
 Give IV antiviral agents 360 366 369
IV antiviral cost of $1000 per day
 Give no IV antiviral agent — — —
 PCR testing, then start IV antiviral agents 331 154 53
 Start IV antiviral agents, then PCR
testing
396,739 396,739 396,739
 Give IV antiviral agents 738 740 740
Pandemic Influenza Scenario With Twice the Seasonal Influenza Mortality
IV antiviral cost of $100 per day
 PCR testing, then start IV antiviral agents — — —
 Start IV antiviral agents, then PCR
testing
39,674 39,674 39,674
 Give no IV antiviral agent Dominated by start IV
antiviral agents, then PCR
testing
Dominated by start IV
antiviral agents, then PCR
testing
Dominated by start IV antiviral
agents, then PCR testing
 Give IV antiviral agents 68 68 68
IV antiviral cost of $500 per day
 PCR testing, then start IV antiviral agents 32 — —
 Give no IV antiviral agent — Dominated by PCR testing,
then start IV antiviral agents
Dominated by PCR testing,
then start IV antiviral agents
 Start IV antiviral agents, then PCR
testing
198,370 198,370 198,370
 Give IV antiviral agents 363 366 363
IV antiviral cost of $1000 per day
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Variable
IV Antiviral Efficacy in Reducing Hospital Stay by 1 d, ICER
25% 50% 75%
 Give no IV antiviral agent — — Dominated by PCR testing,
then start IV antiviral agents
 PCR testing, then start IV antiviral agents 283 90 —
 Start IV antiviral agents, then PCR
testing
396,739 396,739 396,739
 Give IV antiviral agents 739 736 736
ICER indicates incremental cost-effectiveness ratio (in US $ per QALY); IV, intravenous; PCR, polymerase chain reaction; QALY, quality-
adjusted life-year.
a
In a patient aged 20 years (influenza prevalence, 10%) given 1 dose per day for a 5-day treatment course. Dash mark (—) indicates the best
strategy compared with all other strategies.
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Table 3
ICERs of Different Intravenous Antiviral Strategies in the Nonventilated Population From the Third-Party
Payer Perspectivea
Variable
IV Antiviral Efficacy in Reducing Hospital Stay by 1 d, ICER
25% 50% 75%
Seasonal Influenza Scenario
IV antiviral cost of $100 per day
 PCR testing, then start IV antiviral agents — — —
 Start IV antiviral agents, then PCR testing 39,674 39,674 39,674
 Give no IV antiviral agent Dominated by start IV
antiviral agents, then PCR
testing
Dominated by start IV
antiviral agents, then PCR
testing
Dominated by start IV
antiviral agents, then PCR
testing
 Give IV antiviral agents 802 800 790
IV antiviral cost of $500 per day
 Give no IV antiviral agent — — —
 PCR testing, then start IV antiviral agents 1733 1484 1301
 Start IV antiviral agents, then PCR testing 198,370 198,370 198,370
 Give IV antiviral agents 4266 4201 4236
IV antiviral cost of $1000 per day
 Give no IV antiviral agent — — —
 PCR testing, then start IV antiviral agents 6438 5473 5176
 Start IV antiviral agents, then PCR testing 396,739 396,739 396,739
 Give IV antiviral agents 8666 8596 8536
Pandemic Influenza Scenario With Twice the Seasonal Influenza Mortality
IV antiviral cost of $100 per day
 PCR testing, then start IV antiviral agents — — —
 Start IV antiviral agents, then PCR testing 39,674 39,674 39,674
 Give no IV antiviral agent Dominated by start IV
antiviral agents, then PCR
testing
Dominated by start IV
antiviral agents, then PCR
testing
Dominated by start IV
antiviral agents, then PCR
testing
 Give IV antiviral agents 789 794 797
IV antiviral cost of $500 per day
 Give no IV antiviral agent — — —
 PCR testing, then start IV antiviral agents 1499 1171 972
 Start IV antiviral agents, then PCR testing 198,370 198,370 198,370
 Give IV antiviral agents 4310 4202 4290
IV antiviral cost of $1000 per day
 Give no IV antiviral agent — — —
 PCR testing, then start IV antiviral agents 5554 4732 3876
 Start IV antiviral agents, then PCR testing 396,739 396,739 396,739
 Give IV antiviral agents 8506 8553 8571
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ICER indicates incremental cost-effectiveness ratio (in US $ per QALY); IV, intravenous; PCR, polymerase chain reaction; QALY, quality-
adjusted life-year.
a
In a patient aged 20 years (influenza prevalence, 10%) given 1 dose per day for a 5-day treatment course. Dash mark (—) indicates the best
strategy compared with all other strategies.
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